DTSOF yields 7.70% · JNJ yields 2.14%● Live data
📍 DTSOF pulled ahead of the other in Year 1
Combined, DTSOF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DTSOF + JNJ for your $10,000?
DTS Corporation provides systems integration services in Japan. The company operates through four segments: Finance and Society; Corporate Solutions; Operational Infrastructure BPO; and Regional, Overseas, Etc. It develops and maintains information systems; designs and constructs electrical and telecommunications construction work related to information systems; develops, sells, and leases educational equipment and teaching materials related to the information systems; and publishes, edits, and translates work related to the information systems. The company also installs, operates, and maintains computer systems and networks; manufactures, develops, sells, and leases information related equipment comprising computers and software; processes and provides information and commercial transactions; produces, sells, and leases multimedia related content; and acquires, develops, licenses, manages, and transfers intellectual property, such as copyrights and know-how. In addition, it engages in worker dispatch business; and contracting for planning, investigating, researching, training, educating, and consulting activities related to information systems. Further, the company offers enterprise resource planning solutions; and network integration services. It serves finance, telecommunications, and public sector comprising medical welfare, pension authorities, and local governments. DTS Corporation was incorporated in 1972 and is headquartered in Tokyo, Japan.
Full DTSOF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.